Angiotensin AT$_2$ Receptor Contributes towards Gender Bias in Weight Gain

Preethi Samuel$^1$, Mohammad Azhar Khan$^1$, Sourashish Nag$^1$, Tadashi Inagami$^2$, Tahir Hussain$^{1,*}$

$^1$Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas, United States of America, $^2$Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America

Abstract

Obesity is a major disease condition, in turn leading to pathological changes collectively recognized as metabolic syndrome. Recently angiotensin receptor AT$_2$R has been associated negatively with body weight (BW) gain in male mice. However, the gender differences in AT$_2$R and BW changes have not been studied. To understand the gender based role of AT$_2$R involving BW changes, we fed male and female wild type (WT) and AT$_2$R knock out (AT$_2$KO) mice with C57BL6 background with high fat diet (HFD) for 16 weeks. The male AT$_2$KO had higher HFD calorie intake (WT: 1280±80; AT$_2$KO:1680±80 kcal) but gained less BW compared with the WT (WT: 13; AT$_2$KO: 6 g). Contrary to the male animals, the female AT$_2$KO mice with equivalent caloric intake (WT: 1424±48; AT$_2$KO:1456±80 kcal) gained significantly more BW than the WT mice (WT: 9 g; AT$_2$KO: 15 g). The male AT$_2$KO on HFD displayed lower plasma insulin level, less impaired glucose tolerance (GT), and higher plasma T3 compared with WT males on HFD; whereas the female AT$_2$KO mice on HFD showed elevated levels of plasma insulin, more impaired GT, lower plasma T3 and higher free fatty acid and hepatic triglycerides compared with WT females on HFD. Interestingly, compared with WT, AT$_2$KO female mice had significantly lower estrogen, which was further reduced by HFD. These results suggest that AT$_2$R in female mice via potentially regulating estrogen may have protective role against BW gain and impaired glucose tolerance and lipid metabolism.

Introduction

Obesity by itself is a major disease condition, which, in turn, leads to a host of associated pathological changes collectively recognized as metabolic syndrome. [1] Renin angiotensin system (RAS) in addition to playing a critical role in regulating blood pressure (BP) and maintaining electrolyte balance has been reported to contribute towards the initiation and progression of metabolic syndrome.[2–4] Actions of angiotensin II, the major peptide hormone of RAS, are mediated via its two receptors namely AT$_1$R and AT$_2$R. [5] Studies suggest that absence or blockade of AT$_1$R in mice results in resistance of diet-induced obesity, improvement of glucose tolerance and insulin sensitivity, and protection against some traits of metabolic syndrome. [6,7] Studies using male AT$_2$KO mice have shown a negative relationship between AT$_2$R and body weight gain, implying that absence of AT$_2$R is associated with lower body weight gain.[8–11] However, these studies have only included male mice.

Gender based differences in both humans and animal models are known to exist with regards to BP regulation, progression of renal damage, inflammation, weight gain and obesity.[12–14] These differences have primarily been attributed to changes and alterations by sex hormones. [9] Estrogen in particular has been implicated in rendering female gender specific protection of physiological changes. [15] Further, many of these selective advantages such as glucose intolerance and vasodilatation in females are potentially brought about by interaction of estrogen with other hormones and receptors such as insulin and recently with AT$_2$R. [16,17] Recent evidence indicates a positive role of AT$_2$R in physiological changes by an independent action as well as by influencing interactions with other components of RAS system including AT$_1$R and angiotensin I converting enzyme 2 (ACE2). [15] While the protective role of AT$_2$R in lowering BP in females has been recently reported, [18] the role of AT$_2$R in gender based changes to body weight is not known. While obesity is described as an overall disorder of energy balance resulting from increase in food intake and/or reduced energy expenditure, it is also symptomatically characterized by impaired glucose tolerance, hyperinsulinemia and enhanced plasma free fatty acids (FFA) that in turn contributes further towards insulin resistance. [19–21] The present study was designed to understand the differential role of AT$_2$R in body weight changes and metabolic parameters between male and female mice. We found that at the end of 16 weeks of high fat diet (HFD), absence of AT$_2$R had opposite effects on the body weight gain, glucose tolerance, and plasma insulin of males and females; and these changes were inversely related to several factors including changes in the estrogen levels, and physiological role of AT$_2$R in males and females.

Methods and Procedures

Animals
C57BL6 breeder pairs (11–12 weeks of age) were obtained from Harlan (Indianapolis, IN) to create F1 WT mice population. The
AT$_2$ knockout females and males with C57BL6 background were used to breed AT$_2$R knockout mice. [22] The F1 generation (3–4 weeks old) of both WT (28 males, 27 females) and AT$_2$K0 mice (18 male; 26 female) were placed either on normal diet (ND with % kcal 29:15:36 protein:fat:carbohydrate) or high-fat diet (HFD with adjusted % kcal 18:60:21 protein:fat:carbohydrate) for 16 weeks. The mice were housed in the University of Houston animal care facility and maintained under a 12-hr light/dark cycle. The ND/HFD and water were provided ad libitum throughout the experiment period. The Institutional Animal Care and Use Committee approved the animal experimental protocols at the University of Houston, Houston, TX.

**Food Intake and Body Weight**

To determine the direct impact of food intake differing in caloric content on body weight, we measured the food intake throughout the length of the study. Since mice thrive in a social group for a long-term study like the present, with the exception of a few aggressive male mice, the mice was housed in social groups of 2–4 animals in each cage. Weekly 100 g of food in the form of pallet was placed in the food slot of the mice cages. At the end of each week the remaining food, including any fallen bits, was weighed on an electronic weighing scale (Denver instrument P-602) and the amount subtracted from the initial 100 g to account for the food consumed. The total intake of each cage was then divided by the number of mice in the cage. Three days prior to sacrifice, the mice were placed individually in metabolic cages to record the total intake, water intake, urine output and other parameters for single mouse. The food intake in the different groups was calculated in terms of caloric content. We measured the change in body weight in the different groups of mice to assess the effect of the diet and treatment on the body weight. Body weight in the different groups also was measured every week for each animal on a triple beam veterinary scale (Ohaus 700-00 veterinary balance) and measured as change in body weight over basal, which was weight measured at the start of the dietary regimen.

**Glucose Tolerance Test (GTT)**

While obesity is described as an overall disorder of energy balance resulting from increase in food intake and/or reduced energy expenditure, it is also symptomatically characterized by impaired glucose metabolism which further contributes towards glucose intolerance.[19–21] To study the effect of HFD feeding on carbohydrate metabolism, a standard GTT was performed in fasting animals. Briefly, in week 16 of the dietary regimen, the mice of different groups were fasted for 6 hours and given 25 mmol of glucose through intraperitoneal injection. The blood glucose was measured by pricking the tail of conscious animals at 0, 15, 30, 60, 120 and 180 minutes using a glucometer.

**Plasma and Urine Collection, and Gonadal Fat Removal**

Prior to the termination of experiment all animals were individually housed in mouse metabolic cages for 3 consecutive days for urine collection. At the end of 16-weeks treatment, the mice were euthanized by cervical dislocation under anesthesia following 6 hours of fasting. Plasma was collected and stored at −80°C until further use. Gonadal fat depot is the largest dissectable fat pad in rodents and accounts for 30% of all removable fat whose mass has been used as an index of obesity. Therefore, to correlate changes in body weight with the fat content, we measured the mass of gonadal fat depot in the different groups. Paired-gonadal adipose depot (surrounding the epididymus and testes in males, and uterus and ovaries in females) were removed, pat dry on tissue paper and weighed.

**Enzyme-linked Immunosorbent Assay (ELISA) for Plasma Insulin and Tri-iodothyronine (T3)**

Hyperinsulinemia is an index of insulin resistance which is known to correlate with obesity. Furthermore, AT$_2$R deficiency has been shown to prevent diet-induced insulin resistance in male mice. [8] Therefore, we measured the plasma insulin levels to assess gender based role of AT$_2$R on insulin resistance in HFD-induced obesity. Plasma insulin and T3 levels in different groups were determined using ELISA kit as per the manufacturer’s instructions. For insulin, 5 µl of blank, standard, and sample with 95 µl of sample diluent was added in duplicates to appropriate wells. The plate was incubated for 2 hours at room temperature (RT). The wells were washed 5 times and 100 µl of anti-insulin enzyme conjugate was added to each well and incubated for 30 min at room temperature. The wells were washed 7 times, 100 µl of enzyme substrate was added and incubated in dark for 40 min. 100 µl of stop solution was added to stop the reaction and absorbance was measured on a micro-plate reader (BMG LABTECH, Inc Cary, NC) at A$_{450}$ and subtracted from A$_{630}$ values. Since obesity is associated with metabolic/physiological changes either contributed by or as a result of alterations in the endocrine system, we measured a critical metabolic hormone T3, whose plasma level is known to positively correlate with metabolic rate. [23] For T3 levels, the microplate-wells were formatted and 25 µl of appropriate serum reference, control or sample added into assigned wells in duplicates. 100 µl of working T3-enzyme conjugate solution was added to all wells and incubated for 60 min at room temperature with shaking. Following incubation the wells were washed 3 times and 100 µl of TMB substrate solution was added to all wells and incubated at room temperature for 15 min. The reaction was stopped by adding 50 µl of stop solution. The absorbance was read at A$_{450}$ within 15 min on the micro-plate reader.

**Free Fatty Acid (FFA) and Triglyceride (TG) Levels**

Obesity is known to be associated with enhanced plasma FFA, which in turn contributes towards insulin resistance.[19–21] Plasma FFA level was measured by colorimetric method using FFA quantitation kit. For hepatic TG, livers were dissected and snap-frozen in liquid nitrogen and stored at −80°C. In brief, lipids were extracted by homogenizing 25 mg liver tissue in 1 ml 5% Triton-X100 in water, then slowly heated to 80°C in water bath for 5 min. The samples were cooled down and again heated to solubilize all triglycerides into solution. The samples were centrifuged for 5 min and supernatants were diluted 10 fold with dH$_2$O for quantification.

**Enzyme Immune Assay (EIA) for Urinary 17-β-estradiol**

Low levels of estrogen could lead to accumulation of fat mass and development of obesity and hyperlipidemia in females. [9,24] Estrogen also has been shown to have a positive interaction with AT$_2$R. [25,26] In light of this information, we measured urinary estradiol (E2) levels in both male and female animals to investigate a correlation/explanation of body weight changes with estrogen in both genders. Extraction from the urine samples was done by mixing the individual samples with methylene chloride and allowing layers to separate. The extraction was repeated twice and methylene chloride layer was separated followed by evaporation at 30°C. The residue was dissolved in 0.5 ml of EIA buffer. Estradiol level in different groups of female mice was determined.
by taking 50 μl of appropriate blank, standard or sample into assigned wells in duplicates. After adding estradiol tracer and EIA antiserum to appropriate wells, the plate was incubated at room temperature for 1 hour. The plate was developed by adding 200 μl of Ellman’s reagent to each well and incubating in dark on orbital shaker for 90 min. The absorbance was read at A410 on the microplate reader. The data was calculated for 17β-estradiol excreted in 24 hr urine.

**Chemicals**

The HFD feed Teklad custom research diet (catalogue # TD.06414) with adjusted calorie diet (60/Fat) containing 18.4% protein, 21.3% carbohydrate and 60.3% fat, and normal diet 7022 with isocaloric 29% protein, 56% carbohydrate and 15% fat were purchased from Harlan, Indianapolis, IN. Both diets contained similar mineral mix AIN-93G-MX (94046) and vitamin mix AIN93-VX (94047). The Ultra-Sensitive mouse ELISA kit catalog # 90080 from Crystal Chem. Inc. Downers Grove, IL was used for Plasma T3. Plasma free fatty acid levels was measured by free fatty acid quantification kit (Abcam-cat # ab65336, USA). Hepatic TG was analyzed using the triglyceride quantification kit (Abcam-cat # ab65336, USA). The Estradiol EIA kit 96 solid wells, EIA kit catalog # 582251 from Cayman Chemical, Ann Arbor, MI was used for estradiol.

**Statistics**

Data are presented as mean±SEM. The data were analyzed using GraphPad Prism 5 (GraphPad software, San Diego, CA) and subjected to one-way ANOVA with Newman-keuls post hoc test and Student’s unpaired t test. A p value of less than 0.05 was considered statistically significant. Power analysis was performed on groups with higher internal variation to determine statistical significance.

**Results**

**Food Intake**

The food intake was calculated in terms of total kilo calorie (kcal) consumed over 16 weeks. We found no significant difference in the kcal consumption of ND among the males and females of either WT or AT2KO (Figure 1). However, the kcal intake was significantly higher in the HFD-fed group compared to their respective ND-fed controls (for males WT P = 0.005; AT2RKO P = 0.001 and for females WT P = 0.0001; AT2RKO P = 0.0002). Furthermore, the AT2KO male mice on HFD had significantly higher kcal consumption compared with WT males on HFD (P = 0.01) (Figure 1).

**Body Weight**

Weight gain pattern in male and female AT2KO mice on HFD clearly was opposite. In males HFD had a similar effect on body weight gain in both WT and AT2KO. In WT starting from comparable body weights, HFD caused significant increase (28±1 g) compared with ND (15±0.8 g) (P = 0.002) with net difference in 13 g. On the other hand, the difference between AT2KO males on HFD (27±0.3 g) and AT2KO on ND (19±3 g) was attenuated to 8 g. This difference in AT2KO weight on ND and HFD, in part could be attributed to increased weight in AT2KO on ND. Contrary to the males, AT2KO female mice on ND (15±0.3 g) as well as on HFD (30±1.1 g) gained body weight significantly greater than WT on ND (11±1.2g) and WT on HFD (20±1 g), respectively (Figure 2B). We also examined the slope of weight gain curves over 16 weeks. Following are the slopes: males (WT-ND 0.23±0.03; WT-HFD 1.31±0.02) (P = 0.0001), (AT2KO-ND 0.55±0.04; AT2KO-HFD 1.27±0.02) (P = 0.0001); females (WT-ND 0.14±0.0; WT-HFD 0.95±0.03) (P = 0.0001); (AT2KO-ND 0.40±0.01; AT2KO-HFD 1.77±0.07) (P = 0.0001). The data suggest that HFD caused changes in the slope of weight gain in both WT and AT2KO males and females. However, the slope of weight gains in WT males on HFD and AT2KO males on HFD are similar, but there was a significant increase in AT2KO females on HFD compared with WT females on HFD. To determine the overall pattern of weight changes in various groups, we determined area under the curve (AUC) of weight gain over 16 weeks. The AUC data in males are: WT-ND 151±1.6 vs. WT-HFD 236±2.7 (P = 0.001) and AT2KO-ND 177±1.8 vs. AT2KO-HFD 226±2.4 and in females are: WT-ND 102±1.3 vs. WT-HFD 151±1.6 and AT2KO-ND 127±1.3 vs. AT2KO-HFD 193±2 (P = 0.001). The data clearly suggests that changes in AUC pattern in males and females are opposite and follow the end point weight gain data in males and females after 16-weeks of dietary regimen. In males, the AUC increase (49 units) in AT2KO HFD over ND was lesser than the AUC increase (85 units) in WT HFD over ND. Contrarily, in females the AUC increase (66 units) in AT2KO HFD over ND was greater than the AUC increase (49 units) in WT HFD over ND.

** Gonadal Adipose Depot Mass**

As shown in figure 3, in WT males, HFD significantly increased the epididymal fat pad weight (1.2±0.02 g) compared with ND (0.4±0.01 g) (P = 0.0001). The AT2KO males on HFD gained (0.9±0.06 g) significantly higher fat mass compared with AT2KO
Figure 2. Body weight gain in AT2KO mice on high fat diet. Cumulative body weight change (per week) in normal diet (ND) or high fat diet (HFD) fed WT and AT2KO (A) male and (B) female mice. Insets: Total body weight change in 16 weeks. Body weight in the different groups was measured every week for each animal on a triple beam veterinary scale and measured as change in body weight over basal, which was weight measured at the start of the dietary regimen. Data analyzed using one-way ANOVA with Newman-keuls post hoc test and Student t test (p<0.05); n for males (WTND = 13; WTHFD = 15; AT2KOND = 7; AT2KO HFD = 11); n for females (WTND = 7; WTHFD = 20; AT2KOND = 10; AT2KO HFD = 17).

doi:10.1371/journal.pone.0048425.g002
mice on ND (P = 0.001); but there was a significant decrease in epididymal fat weight between male AT2KO and WT on HFD (P = 0.01). On the other hand, AT2KO female mice on HFD (1.26 ± 0.13 g) gained fat weight significantly greater than WT on HFD (0.6 ± 0.09 g) (P = 0.02).

Glucose Tolerance Test (GTT)

Figures 4A and 4B represent the blood glucose over 3 hours period after glucose infusion in male and female mice subjected to 6 hour prior fasting. These blood glucose values measured at the different time points were used to construct glucose curves that were used for calculating GT curve peak and area under the curve (AUC) (Figure 4C &D). The GT curve peak in HFD fed WT (344 ± 27 mg/dL) and AT2KO males (307 ± 15 mg/dL) was significantly higher compared with ND fed WT (217 ± 22 mg/dL) (P = 0.01) and AT2KO (224 ± 17 mg/dL), respectively (Figure 4C). Both the curve peak and AUC in HFD fed AT2KO (curve peak 307 ± 15 mg/dL; AUC 37560 ± 1942) were modestly lower than WT (curve peak 344 ± 27 mg/dL; AUC 42970 ± 1615); however, the decrease was not statistically significant.

On the other hand in females, the GT curve peak in HFD fed WT (269 ± 11 mg/dL) and AT2KO (348 ± 25 mg/dL) was significantly higher compared with their respective ND-fed control groups (P = 0.01- P = 0.001). However, plasma insulin in AT2KO males on HFD (1.26 ± 0.01 mg/dL) was modestly lower than WT on HFD (1.26 ± 0.01 mg/dL) (Figure 5A). Contrary to the males, plasma insulin in AT2KO females on HFD (1.9 ± 0.2 mg/dL) exhibited modestly but significantly greater plasma insulin compared with WT on HFD (1.3 ± 0.2 ng/ml) (P = 0.02) (Figure 5B).

Plasma Insulin

All HFD fed groups, WT and AT2KO males and females, exhibited greater plasma insulin levels compared with their respective ND control groups (P = 0.01- P = 0.001). However, plasma insulin in AT2KO males on HFD (1.26 ± 0.01 mg/dL) was modestly lower than WT on HFD (1.26 ± 0.01 mg/dL) (Figure 5A). Contrary to the males, plasma insulin in AT2KO females on HFD (1.9 ± 0.2 mg/dL) exhibited modestly but significantly greater plasma insulin compared with WT on HFD (1.3 ± 0.2 ng/ml) (P = 0.02) (Figure 5B).

Plasma T3

The HFD had no effect on plasma T3 levels in WT males (ND: 1.26 ± 0.01 ng/mL; HFD: 1.26 ± 0.01 ng/mL) but caused a modest increase in T3 in the AT2KO males (ND: 1.27 ± 0.01 ng/mL; HFD: 1.32 ± 0.02 ng/mL) (P = 0.008) (Figure 6A). On the other hand, the plasma T3 levels were not affected by HFD in female mice, WT or AT2KO, compared with females on ND (Figure 6B). However, AT2KO females on ND (1.17 ± 0.02 ng/mL) exhibited lower plasma T3 levels compared with WT females on ND (1.26 ± 0.01 ng/mL) (P = 0.001) (Figure 6B).

Plasma Free Fatty Acids (FFA) and Hepatic Triglycerides (TG)

The HFD caused a significant increase in plasma FFA (Figure 7A) and hepatic TG (Figure 7B) in both the WT and AT2KO males. AT2KO males on HFD had significantly (P = 0.05) lower TG (21.2 ± 2 mg/g tissue) compared with HFD fed WT (TG: 25 ± 0.1 mg/g tissue). The FFA in AT2KO males on HFD (20.1 ± 1.3 mg/dL) were modestly, but non-significantly, reduced compared with HFD WT (22 ± 0.6 mg/dL). In females, both WT and AT2KO on HFD had elevated plasma FFA (Figure 7A) and hepatic TG (Figure 7B) compared with their respective controls;
but the increase in FFA and TG was much greater in AT2KO females (FFA: 24 ± 6 mg/dL (P = 0.0002); TG: 49 ± 6 mg/dL (P = 0.002) compared with WT females on HFD (FFA: 18 ± 6 mg/dL (P = 0.0001); TG: 37 ± 2 mg/dL (P = 0.005)).

Urinary 17-β-estradiol

The urinary estradiol (E2) level in the WT female mice on HFD (19 ± 1.5 ng/24 hr) was lower compared with the WT females on ND (46 ± 4 ng/24 hr). Interestingly, the urinary E2 level in the AT2KO female mice on ND (27 ± 1.3 ng/24 hr) was significantly lower than WT females (P = 0.0001) and was further reduced by HFD (9 ± 0.6 ng/24 hr) (P = 0.0001) (Figure 8B). The urinary E2, even though a predominant female hormone, also was measured in male mice (Figure 8A). The E2 levels in males are in a much lower ranges. However, the urinary E2 levels in the WT male mice on HFD (0.12 ± 0.01 ng/24 hr) was significantly lower compared with the WT males on ND (0.37 ± 0.03 ng/24 hr) (P = 0.0001). Similarly, the E2 levels in the AT2KO male mice on HFD (0.23 ± 0.01 ng/24 hr) was significantly lower compared with AT2KO males fed on ND (0.33 ± 0.01 ng/24 hr) (P = 0.0001), but was significantly greater than WT on HFD (P = 0.0001) (Figure 8A).

Discussion

In the present study, we found that AT2KO males on HFD had lesser body weight gain, lower gonadal adipose depot weight, lower levels of plasma insulin less impaired glucose tolerance (GT), higher plasma T3 and higher urinary estrogen levels, compared with HFD fed WT males. In contrast to the males, AT2KO females on HFD had significantly higher body weight, higher gonadal adipose depot weight, elevated levels of plasma insulin,
indicating the basal levels of T3 in AT2KO to be inherently lower and not subject to changes by dietary manipulation. However, the changes in T3 levels are very modest; whether such changes in T3 are able to affect the metabolic rate is not clear.

The weight gain pattern of AT2KO males in our study concurs with other reports showing that AT2KO mice in response to HFD had a lower rate of weight gain compared to the WT mice. [8,11] Moreover, these studies showed that inhibition of AT2R improved insulin sensitivity and caused fat loss, by influencing insulin signaling pathway and control of adipose tissue metabolism. On the other hand, although there is a study linking AT2R A/C3123 polymorphism with increased body mass index in Japanese women, [27] ours is the first study demonstrating that lack of AT2R results in the greater weight gain in female animals placed on HFD.

In mice of the eight major adipose depots four are present in the abdominal cavity. Gonadal depot present in the abdominal cavity is the largest dissectable adipose depot, [28] consisting of 30% dissectable fat. [29] A cluster of metabolic disorders and diseases have been closely associated with abdominal obesity in humans. [30] The changes in body weight gain in the present study are associated with parallel changes in the gonadal adipose depot in both WT and AT2KO mice on HFD (Figure 3). The changes in the fat mass suggest that AT2R differentially affects fat metabolism in males and females and contributes to body weight gain in response to HFD.

In order to explain the gender based role of AT2R in weight gain, we measured urinary estrogen, which serves as an index of endogenous estrogen levels (Figure 8). [31] There are number of sites of estrogen biosynthesis such as mesenchymal cells of adipose tissue and skin, [32] osteoblasts, [33] different region in the brain, [34] however ovaries are the main site for estrogen production in premenopausal nonpregnant women. The extragonadal sites of estrogen biosynthesis have several fundamental features differing from those of the ovaries and become major sources of estrogen beyond menopause. [32] In the present study female mice are comparable to the premenopausal stage and therefore ovaries are considered as primary source of the estrogen measured. Therefore based on the stage of the mice’s life cycle, length of the dietary treatment, we do not expect any major consequences due to the AT2R knock out status. However if HFD is continued on an aging mice population we could potentially see some additional worsening of the metabolic state in the mice.

While estrogen is a female hormone produced in higher quantity in females and known to regulate body weight gain, [24] there is evidence that male estrogen also plays a role in male body weight gain and influence fat metabolism. [35] Cells of the testes [36] produce estrogen, however testicular contribution for circulating estrogens at best is only 15% [37] making local production of estrogens, both intra testicular and extragonadal, physiologically significant. Nevertheless, since the levels of circulating estrogen in males compared to the females are so negligible in this study that in light of the large differential weight gain in females, actual site of estrogen biosynthesis in males does not seem very significant. There are evidences suggesting a positive regulatory interaction between female estrogen and AT2R; estrogen upregulates AT2R expression in the kidney, heart and reproductive organs. [15,16,25] Alternatively, stimulation of AT2R in ovarian granulose cells can induce ovulation and oocyte maturation, and increase estrogen production. [26] Consistent to these studies, we observed reduction in estrogen in AT2KO female mice in the present study. On the other hand, there are no reports on a potential interaction between male estrogens and AT2 receptor; however, we found that HFD caused a decrease in WT

more impaired GT, lower plasma T3 and estrogen levels, compared to HFD fed WT female mice. Additionally, the urinary E2 in AT2KO females on ND was lower compared with WT on ND.

Excessive weight gain or obesity is generally associated with hyperinsulinemia, impaired glucose tolerance and blood pressure increase [19–21]. Moreover, obesity and associated metabolic/physiological changes are contributed by or result in the alterations in various hormone systems, including thyroid hormone. [23] In the present study, we observed that plasma T3 was increased in the AT2KO males following 16 wk of HFD treatment (Figure 6). However, in AT2KO females T3 levels were significantly lower compared to the WT. Although, we have not measured metabolic rate or related parameters, changes in plasma T3 AT2KO mice indicates a possible slowing down of basal metabolic rate in AT2KO female mice. Interestingly, the T3 levels of ND fed AT2KO female were not different from AT2KO on HFD.
male urinary estrogen. The decrease was less pronounced in AT2KO male mice on HFD compared with WT on HFD, suggesting an inverse relationship between AT2R and male estrogen production.

Estrogen insufficiency is thought to be largely responsible for increased adiposity and abdominal fat gain during menopause. [9] Studies show post-menopausal women, ovariectomized mice, and mice lacking estrogen receptor-α or aromatase have increased fat mass, and develop obesity and hyperlipidemia. [4,9,35,38]

Additionally, physical inactivity has been observed in obese aromatase deficient rodents and in women transitioning to menopause. [4,39] Based on our observations, we speculate that depletion of AT2R dysregulates estrogen level and thus function is compromised. Since adipose tissue also express both the AT2R and estrogen producing pathway, [8,10,40–41] absence of AT2R can cause a decrease in adipose estrogen production locally that

Figure 7. Effect of high fat diet on plasma hepatic free fatty acids and hepatic triglycerides in AT2KO mice. Plasma FFA (A) and Hepatic triglycerides (B) levels in male and female WT or AT2KO mice either on normal diet (ND) or high fat diet (HFD). Plasma FFA level was measured by colorimetric method using FFA quantification kit. Hepatic TG level was measured by colorimetric method using TG quantification kit. Data analyzed using one-way ANOVA with Newman-keuls post hoc test and Student t test (p<0.05). In plasma FFA, n for males (WTND = 3; WTHFD = 3; AT2KOND = 3; AT2KO HFD = 3); n for females (WTND = 7; WTHFD = 3; AT2KOND = 3; AT2KO HFD = 3). For hepatic triglycerides, n for males (WTND = 4; WTHFD = 3; AT2KOND = 4; AT2KO HFD = 3); n for females (WTND = 3; WTHFD = 3; AT2KOND = 3; AT2KO HFD = 4).

doi:10.1371/journal.pone.0048425.g007
could affect adipose tissue metabolism. Further increase in the body weight of AT2KO females when put on HFD may be due to compromised interaction between estrogen and insulin as well (Figure 2). It has been shown that chronic estrogen supplement in mice reduces the occurrence of HFD-induced insulin resistance, and improves glucose use rate. [24] In the present study, we demonstrated that HFD elicits profound reduction of estrogen level in female AT2KO that could have a negative effect on insulin and its function resulting in an increase in body weight and impaired glucose tolerance. These typical symptoms of metabolic syndrome may in turn further exacerbate weight gain due to compounding effect of the syndrome. As expected, the changes in plasma FFA and hepatic TG are aligned with changes in body weight gain, glucose tolerance and plasma insulin in WT and AT2KO male and females on HFD. Inasmuch as enhanced plasma FFA is indicative of impaired lipid metabolism, [42] plasma FFA also contributes to glucose intolerance and insulin resistance. [43,44] Overall, the findings in this study indicate that differential changes in estrogen may be a potential basis of the gender bias role of AT2R in weight gain. Estrogen has also been implicated to regulate leptin an important hormone that regulates energy balance and food intake. [45,46] There are studies suggesting that reduced estrogen associated weight gain and increased food intake may not be entirely associated with reduction in leptin. [9,47] Moreover, since we did not observe any changes in caloric intake, (Figure 1) we speculate that affects of AT2R through estrogen on body weight gain may not involve leptin. However, the molecular mechanisms of AT2R-mediated regulation of estrogen in males and females, and in turn, the role of estrogen in AT2R-mediated weight gain need further investigation.

While estrogen could be a potential regulatory mediator in studying gender bias role of AT2R in weight gain as discussed above, other mechanisms cannot be ruled out. In previous studies, AT2R is suggested to promote adipocyte differentiation and lipogenesis. [48] Genes such as lipoprotein lipase, aP2 and CD36 proteins along with PPARγ are implicated in AT2R-mediated lipogenesis in adipocytes. [4,49] While we have not measured these parameters, role of AT2R in lipogenesis in male mice may be attributed from our observation that there was a reduced adipose weight gain in AT2RKO mice on HFD. However, the results were quite opposite in females. There is study suggesting that estrogen or its metabolite may serve as an endogenous ligand for PPARγ [32] whose activation is known to improve insulin resistance and metabolism, [50–52] also seen in females in the present study. Whether such mechanisms make the basis for the gender biased role of AT2R in weight gain needs systematic investigation.

The present study provides a unique and novel perspective of the gender biased role of AT2R on body weight gain and other metabolic parameters. Differential regulation of estrogen by AT2R may be responsible in part for leading to gender bias body and fat weight gain and related effects such as glucose tolerance. However certain additions to the study would have provided a keener insight into the mechanistic aspects. These include metabolic and body composition analysis to determine the precise lipogenic/lipolytic factors contributing towards the weight gain. Effects of manipulation of estrogen by ovariectomy and estrogen replacement, globally as well as in metabolic tissues such as thyroid and fat, will be important to strengthen the AT2R-estrogen hypothesis. Additionally, along with the gender biased effect of AT2R, it would be interesting to know the effect of other RAS components such as AT1 receptor, angiotensin converting enzyme (ACE), ACE2 and renin, which are inter-regulatory. The present study paves way for future studies that could expand the scope of therapeutic potential of AT2R in metabolic disorders particularly in postmenopausal women.

**Author Contributions**

Conceived and designed the experiments: PS MAK TH. Performed the experiments: PS MAK SN. Analyzed the data: PS MAK TH. Contributed reagents/materials/analysis tools: TH TL. Wrote the paper: PS TH.
Angiotensin AT2 Receptor and Weight Gain

References

1. Luis AJ, Attie AD, Reue K (2008) Metabolic syndrome: from epidemiology to systems biology. Nat Rev Genet 9: 819–830.

2. Armando I, Jezova M, Juorio AV, Terron JA, Falcon-Neri A, et al. (2002) Angiotensin II upregulates renal angiotensin II receptor subtype. Endocrinology 147: 5078–5086.

3. Yvan-Charvet L, Massiera F, Lamande N, Ailhaud G, Teboul M, et al. (2009) Deficiency of angiotensin type 2 receptor-deficient mice. Endocrinology 150: 1421–1428.

4. Sandberg K, Ji H (2008) Why can’t a woman be more like a man?: Is the renin-angiotensin system gender-differentiatable? J Clin Endocrinol Metab 93: 801–805.

5. Kouyama R, Suganami T, Nishida J, Tanaka M, Toyoda T, et al. (2005) Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinology 150: 1421–1428.

6. Miller JA, Anacta LA, Cattran DC (1999) Impact of gender on the renal response to angiotensin II. Kidney Int 55: 378–385.

7. Sampson AK, Widdop RE, Denton KM (2008) Sex-differences in circadian blood pressure variations in response to chronic angiotensin II infusion in rats. Clin Exp Pharmacol Physiol 35: 391–395.

8. Delarue J, Magnan C (2007) Free fatty acids and insulin resistance. Curr Opin Lipidol 18: 363–368.

9. Boden G (1997) Role of fatty acids in the pathogenesis of insulin resistance and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 32 Suppl 3: 14–23.

10. Boden G (1997) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes: 46: 3–10.

11. Naftolin F, Ryan KJ, Davies IJ, Reddy VV, Flores F, et al. (1975) The formation of estrogens by central neuroendocrine tissues. Recent Prog Horm Res 31: 295–349.

12. Shimizu H, Shimomura Y, Nakanishi Y, Futawatari T, Ohtani K, et al. (1997) Angiotensin II induces ovulation and oocyte maturation in rabbit ovaries via the AT2 receptor subtype. Endocrinology 137: 1204–1211.

13. Hemsell DL, Grodin JM, Brenner PF, Sizeri PK, Macdonald PC (1974) Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 39: 701–705.

14. Grumbach MM, Auchus RJ (1999) Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 84: 4677–4694.

15. Felig P, Taylor JA, Iwamoto GA, Lahmann DB, Cooke PS (2000) Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci U S A 97: 12729–12734.

16. Bruch HR, Wolf L, Buddle R, Romalo G, Schweikert HU (1992) Androsterone metabolism in cultured human osteoblast-like cells. J Clin Endocrinol Metab 75: 101–105.

17. Bocea M, Dugail I, Standridge M, Claycombe K, Chun J, et al. (2001) Angiotensin II upregulates renal angiotensin II AT2 receptors. Am J Physiol Renal Physiol 283: F934–F943.

18. Fouad MF, Ryan KJ, Davies IJ, Reddy VV, Flores F, et al. (1975) The formation of estrogens by central neuroendocrine tissues. Recent Prog Horm Res 31: 295–349.

19. Ikeda H, Yamauchi T, Hara T, Mima Y, Sato H, et al. (2000) Activation of PPARgamma by angiotensin II type 1 receptor blockers induce adiponectin. Hypertension 46: 143–148.

20. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, et al. (2006) Molecular activation of PPARgamma by angiotensin II type 1 receptor antagonists. Vasc Pharmacol 45: 154–162.

21. Black AE, Goldberg GR, Jebl SA, Livingstone MB, Cole TJ, et al. (1991) Critical evaluation of energy intake data using fundamental principles of energy physiology. 2. Evaluating the results of published surveys. Eur J Clin Nutr 45: 583–599.

22. Shi T, Labosky PA, Wagenknecht LE, Siiteri PK, MacDonald PC, et al. (1974) Plasma androstenedione and estrone concentrations. J Clin Endocrinol Metab 39: 701–705.

23. Tsukada T, Nakamura T, Takahashi K, Imamura K, Sugawara M, et al. (2003) Angiotensin II upregulates renal angiotensin II AT1 and AT2 receptors in the rat. Regul Pept 115: 171–176.

24. Naito N, Yamada T, Sato H, Takenaka Y, Hara T, et al. (2000) Expression of angiotensinogen in adipose tissue. Am J Physiol Regul Integr Comp Physiol 293: R574–R584.

25. Naito N, Ryan KJ, Davies IJ, Reddy VV, Flores F, et al. (1975) The formation of estrogens by central neuroendocrine tissues. Recent Prog Horm Res 31: 295–349.

26. Yoshimura Y, Karube M, Aoki H, Oda T, Koyama N, et al. (1996) Angiotensin II induces ovulation and oocyte maturation in rabbit ovaries via the AT2 receptor subtype. Endocrinology 137: 1204–1211.

27. Kusama K, Nakane N, Saiga K, Tsuzuki K, Sano Y, et al. (2007) The angiotensin II receptor subtype. Endocrinology 148: 84689.

28. Armando I, Jezova M, Juorio AV, Terron JA, Falcon-Neri A, et al. (2002) Angiotensin II upregulates renal angiotensin II receptor subtype. Endocrinology 147: 5078–5086.

29. Sampson AK, Widdop RE, Denton KM (2008) Sex-differences in circadian blood pressure variations in response to chronic angiotensin II infusion in rats. Clin Exp Pharmacol Physiol 35: 391–395.

30. Kissebah AH, Krakower GR (1994) Regional adiposity and morbidity. Physiol Rev 74: 761–811.

31. Thomas HV, Reeves GK, Key TJ (1997) Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 8: 9–15.

32. Simpson E, Rubin G, Clyne C, Robertson K, O’Donnell L, et al. (1999) Local estrogen bioavailability in males and females. Endocr Relat Cancer 6: 131–137.

33. Bruch HR, Wolf L, Buddle R, Romalo G, Schweikert HU (1992) Androsterone metabolism in cultured human osteoblast-like cells. J Clin Endocrinol Metab 75: 101–105.